A 49-year-old woman presented with crustuous efflorescences covering ≈ 70% of an erythematous skin (Fig. 1). She developed hypotension and a partially compensated metabolic acidosis (pH: 7.16; pCO2: 32 mmHg).
Fig. 1
A 49-year-old female patient after allogeneic hematopoietic stem cell transplantation for Hodgkin’s lymphoma with classical signs of crusted scabies
×
Allogeneic hematopoietic stem cell transplantation from a matched unrelated donor following myeloablative conditioning including anti-T-lymphocyteglobulin had been performed 2 months prior to treat relapsed stage IVB Hodgkin’s lymphoma. A localized scabies infection occurring at the end of the aplastic phase was treated with ivermectin in the recommended dose of 200 µg/kg bodyweight on days 1 and 8, each. After transplantation, visits to the outpatient unit frequently deviated from schedule, clinical status was poor, and cyclosporine levels were below target level.
Anzeige
Scabies crustosa, historically referred to as scabies norvegica, and septic shock were diagnosed. Despite fluid and vasopressor resuscitation, antimicrobial, anti-parasitic and anti-inflammatory drug treatment, continuous renal replacement therapy, and respiratory support, she died due to multi-organ failure 1 day after initial presentation. Blood cultures taken the day before grew Enterococcus faecium.
Scabies is a parasitic disease caused by the mite Sarcoptes scabiei var. hominis [1]. In Western Europe, scabies can be of concern in communities with social problems, and in patients with risk factors such as promiscuity and advanced age. Due to defective T cell responses, immunosuppressed patients are at increased risk of experiencing crusted scabies, previously referred to as scabies norvegica [2, 3]. Production of complement inhibitors by the mites results in an increased risk for secondary infections caused by streptococci and staphylococci in the affected patients [4]. Treatment options for scabies are systemic oral ivermectin (USA: FDA off-label, EU: EMA approved), or topical permethrin [5].
Acknowledgements
Open Access funding provided by Projekt DEAL.
Compliance with ethical standards
Conflict of interest
MC and DW declare no conflict of interest with regards to this report. No financial support was granted for the preparation of this work.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.
Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.
Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
